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Introduction
Pharmacological stress testing has emerged as an important diagnostic tool in the evaluation 
and management of patients with known coronary artery disease, especially those who cannot perform 
physical exercise. It has also become an important modality to assess myocardial viability, hibernating 
myocardium and valvular heart disease. Unlike exercise stress testing in which cardiac imaging is not  
always  needed,  pharmacological  stress  test  needs  some  form  of  imaging  to  detect  myocardial 
ischaemia. 
Pharmacological stress tests with vasodilatation, using dipyridamole or adenosine, have been 
used  extensively  in  conjunction  with  nuclear  perfusion  imaging1.  Recently  pharmacological  stress 
echocardiography has become an accepted alternative to exercise stress testing and to stress testing 
with nuclear imaging. Many pharmacological agents have been used for stress testing.  Dipyridamole 
and adenosine are used commonly in some places in combination with echocardiographic imaging. 
Dobutamine is the preferred agent in some parts of the world, like the United States. More and more 
cardiac  laboratories  consider  dobutamine  as  the  drug  of  choice  for  stress  testing.  A newer  drug 
Arbutamine is also approved for this purpose.
Aims of the Study
• To  assess  the  myocardial  viability  after  myocardial  infarction  using  dobutamine  stress 
echocardiography
• To  study  the  various  high  risk  variables  that  affect  the  viability  of  the  myocardium after 
myocardial infarction
• To detect the significance of regional wall motion abnormality during the dobutamine stress 
echocardiography in the prediction of coronary events after myocardial infarction
• To evaluate the factors that predict the coronary events and the presence of myocardial viability 
after myocardial infarction
• To stratify the risk of the patients for coronary events following myocardial infarction using the 
dobutamine stress echocardiographic responses at low doses and high doses
• To assess  the  negative  predictive  value  of  dobutamine  stress  echocardiography in  the  post 
myocardial infarction setting
DOBUTAMINE STRESS ECHOCARDIOGRAPHY
Stress Echocardiography
Stress  echocardiography  is  based  on  the  fundamental  causal  relationship  between  induced 
myocardial ischaemia and left ventricular regional wall motion abnormalities. The potential for using 
echocardiography  for  this  purpose  was  first  reported  in  1979  when  two  groups  of  investigators 
demonstrated the proof of concept. Mason and colleagues2 used M-mode echocardiography to study 13 
patients  with coronary artery disease and 11 age matched controls  during  supine  bicycle  exercise. 
Stress induced wall motion changes were observed in 19 of the 22 segments on the stenotic coronary 
artery territory. Although this was the first demonstration of transient ischaemia being detected with 
ultrasound, the inherent limitations of M-mode echocardiography was apparent. Wann and coworkers3 
applied  an  early  2D,  30 degree  sector  imaging  system  to  demonstrate  inducible  wall  motion 
abnormalities during supine bicycle exercise and subsequent improvement of the wall motion response 
after revascularization. These early studies were limited by image quality and a reliance on video tape 
analysis, factors that would slow the growth of the field in its early years. 
In  the  1980s,  improvement  in  image  quality  and  the  development  of  digital  acquisition 
technology or frame grabbers, contributed to greater accuracy and increased the practicality of using 
stress echocardiography in clinical situations. Most important,  the digitization of echocardiographic 
images reduces the problem of respiratory interference by permitting selection of cardiac cycles that 
were devoid of lung interference and the creation of cine loops that permitted side by side analysis of 
rest and stress images. This allowed more accurate interpretation of wall motion, largely by permitting 
relatively  subtle  changes  in  stress  induced  wall  motion,  to  be  detected.  Digital  technology  also 
shortened  the  acquisition  time  for  post  exercise  imaging  and  facilitated  display,  storage  and 
transmission of echocardiographic data. More than any other single factor, the application of digital 
imaging led to the rapid development of stress echocardiography as a clinical tool.
Physiological Basis
In the early days of echocardiography Tennant and Wiggers observed the relationship between 
systolic  contraction  and  myocardial  blood  supplied  to  the  left  ventricle.  With  the  induction  of 
ischaemia, these investigators demonstrated the rapid and predictable development of systolic bulging 
or dyskinesis. This observation established the link between induced ischaemia and transient regional 
myocardial dyssynergy, recorded echocardiographically as the development of wall motion abnormality 
after the application of a stressor.
In the absence of flow limiting coronary stenosis, physiologic stress results in an increase in 
heart rate and contractility that is maintained via an increase in myocardial blood flow. Systolic wall 
thickening, endocardial excursion, and global contractility all increase, leading to a decrease in end 
systolic volume and an increase in the ejection fraction compared with the baseline.  Although this 
response may be blunted in the setting of advanced age and hypertension or in the presence of β-
blocker  therapy,  absence  of  the  hypercontractile  state  in  response  to  stress  should  generally  be 
considered an abnormal response.
In the presence of coronary stenosis, the increase in myocardial oxygen demand that occurs in 
response to stress is not matched by an appropriate increase in supply. If the supply demand mismatch 
persists, a complex sequence of events known as the ischaemic cascade will develop. Soon after the 
development  of  a  regional  perfusion  defect,  a  wall  motion  abnormality  occurs,  characterized 
echocardiographically as a reduction in systolic thickening and endocardial excursion. The severity of 
the wall motion abnormality (hypokinesis vs dyskinesis) will depend on several factors, including the 
magnitude of the blood flow change, the spatial extent of the defect, the presence of collateral blood 
flow, left ventricular pressure and wall stress, and the duration of ischaemia. Deterioration in regional 
wall motion however, is a specific and predictable marker of regional ischaemia that generally precedes 
such traditional manifestations as angina or electrocardiographic abnormalities. 
Once the stressor is eliminated, myocardial oxygen demand decreases and ischaemia resolves. 
Normalization of wall motion abnormality may occur rapidly, although typically the complete recovery 
of normal function takes 1 to 2 minutes, largely depending on severity and duration of ischaemia.  
Stunned myocardium is the term applied when functional abnormalities persist after transient ischaemia 
for  a  longer  period.  Although  a  reversible  process,  stunning  may last  days  or  even  weeks  if  the 
ischaemia is severe and prolonged. 
The utility of echocardiography in conjunction with stress testing is contingent on the ability to 
record  wall  motion  and  left  ventricular  function  at  baseline  and  then  to  detect  changes  after  the 
induction of stress, either exercise or pharmacologic. At baseline, the presence of regional wall motion 
abnormality  generally  implies  the  presence  of  previous  myocardial  infarction.  Less  often 
cardiomyopathy and stunning or hibernating myocardium cause resting wall motion abnormalities.
Historical Development of Dobutamine Stress Echocardiography
Dobutamine was used in the year 1984 for cardiac stress imaging in conjunction with thallium 
scintigraphy and was reported in The American Heart Journal2. Following this report various modalities 
of detecting ischaemia induced by dobutamine, including ECG and echocardiographic imaging were 
reported4.  Coma-Canella4 reported  95%  sensitivity  and  78%  specificity  of  the  dobutamine  stress 
echocardiography using ST changes or angina as markers of positive test in nearly 100 patients. The 
sensitivity and specificity reported with dobutamine stress ECG were much lower.5
At present dobutamine stress testing is almost always used with either echocardiography or 
nuclear imaging. Between these two, echocardiography has emerged as the most powerful tool to detect 
ischaemia. The role of DSE (Dobutamine Stress Echocardiography) has expanded from evaluation of a 
patient with suspected coronary artery disease to include patients with known coronary artery disease, 
post  myocardial  infarction  patients,  cardiac  risk  stratification  prior  to  noncardiac  surgery  and 
assessment of myocardial viability. 
Technical  advancements  and  improvements  in  echocardiographic  image  quality  have 
contributed to increasing use of echocardiography as a means of imaging the heart both during exercise 
and  pharmacological  stress.  The  development  of  digital  imaging  has  enhanced  the  use  of 
echocardiography6 and  especially  DSE.7 The  ability  to  capture  a  single  loop of  cardiac  cycle  and 
display it as a continuous loop with the pre and post exercise images running side by side has greatly 
improved the detection of subtle hypokinesia, increased the ease of use and shortened the reporting 
times.
Pharmacology of Dobutamine
Dobutamine is a synthetic catecholamine developed by Tuttle and Mills8 as an inotropic agent 
with  less  chronotropic  and peripheral  vascular  effects  than  other  catecholamines  like  isoprenaline, 
dopamine  and  norepinephrine.  The  drug  was  developed  in  the  mid  1970s  and  was  first  available 
clinically in 1978. It  was initially used as a positive inotropic agent to augment cardiac output  in 
patients with congestive cardiac failure.9
Dobutamine has a predominant β1 agonist activity.9 It also has a relatively weak β2 and α1 agonist 
activity.9 Through its β1  action it increases the heart rate and contractility with resultant increase in 
cardiac  output.  Peripheral  resistance  may fall  due  to  the  β2  effects.  The  haemodynamic  effects  of 
dobutamine are similar to exercise (increase in heart rate, blood pressure and contractility). There is an 
augmentation of myocardial oxygen demand MVO2 and increase in coronary blood flow in normal 
vessels.10 In the setting of an obstructed coronary artery,  the regional myocardial perfusion may be 
impaired when there is an increased metabolic demand.11
There  is  a  good  correlation  between  dobutamine  dose,  plasma  levels  and  haemodynamic 
effects.9 With a continuous infusion of the drug, the onset of action is within 2 minutes and maximum 
effects  are  seen  at  10  minutes.  Steady state  is  not  achieved  till  the  10 th minute.  The  half  life  of 
dobutamine is about 2 minutes and the drug is eliminated and metabolized in 10 to 12 minutes after the  
termination of a continuous infusion.9 Dobutamine is metabolized by catechol-o-methyltransferase to 
pharmacologically inactive metabolites that are excreted in the urine.9
In  addition  to  the  expected  cardiac  effects,  dobutamine  may  produce  a  lot  of  noncardiac 
symptoms like headache, anxiety and tremors.9 Patients may also develop chills and shivering. 
Pathophysiology of Dobutamine Stress Echocardiography
The clinical applications of DSE rest on the following principles
1. The infusion  of  dobutamine  can  cause  regional  myocardial  ischaemia  in  areas  supplied  by 
obstructed coronary arteries.
2. The regional ischaemia results is systolic contractile dysfunction.
3. The two-dimensional echocardiography is an accurate and reliable imaging modality to detect 
systolic regional dyssynergy and dysfunction.
Dobutamine  increases  MVO2 by  increasing  the  heart  rate  (chronotropic  effect),  myocardial 
contractility (inotropic effect) with a variable effect on blood pressure.11 Dobutamine also influences 
the regional myocardial blood flow.10 The normal response of the myocardium to dobutamine is to 
increase myocardial thickening with an augmentation of ejection fraction. In the setting of obstructive 
coronary artery disease, increases in MVO2 induced by dobutamine result in ischaemia due to supply-
demand mismatch. The ischaemic cascade results initially in diastolic dysfunction, followed by systolic 
dysfunction, ECG changes and finally symptoms of ischaemia. Therefore when areas of myocardium 
become  ischaemic,  echocardiography  may  detect  areas  of  hypokinesis,  akinesis  or  dyskinesis.12 
Reduced regional systolic wall thickening is another finding with myocardial ischaemia. Depending on 
the  response  of  the  nonischaemic  regions,  global  ejection  fraction  may  increase,  fall  or  remain 
unchanged. Regions of the myocardium that are infarcted and have no viable tissue remain hypokinetic 
or akinetic. In the regions with viable and infarcted myocardium, dobutamine may cause an increased 
wall  thickening.  If  this  area  is  supplied  by  a  critically  stenosed  coronary  artery,  they  may  show 
subsequent  worsening  of  contractile  function  (the  so  called  biphasic  response)  at  higher  doses  of 
dobutamine, reflecting viable but ischaemic myocardium.
Several other potential markers of myocardial ischaemia induced by dobutamine may serve as 
adjuncts to an analysis of wall motion. None are currently used alone to define a positive DSE. These 
markers  include  left  ventricular  cavity  dilatation,  alterations  in  transmitral  flow  by  pulsed  wave 
doppler, a decrease in transaortic flow, the development of new worsening mitral regurgitation, the 
development of sinus node acceleration, development of ischaemic ECG changes and the development 
of hypotension.13 Despite some initial enthusiasm, development of ECG changes has shown to be an 
insensitive marker of ischaemia.5 The hypotension following dobutamine also does not mean serious
ischaemia.13
By producing cardiac effects similar to exercise, inducing an increased heart rate, cardiac output 
and systolic blood pressure, with a resultant increase in MVO2, a graded dobutamine infusion provides  
a  rational  alternative  to  exercise  as  a  way to  stress  the  heart  and provoke  myocardial  ischaemia. 
Although  the  ECG  response  is  a  relatively  insensitive  marker  of  ischaemia,  two-dimentional 
echocardiography provides  a  reliable  method of  detecting ischaemia because  regional  wall  motion 
abnormalities are early and predictable response to myocardial ischaemia. Therefore the combination of 
dobutamine and echocardiography provide a reasonable alternative to exercise testing.
Hypotension and Left Ventricular Tract Outflow Obstruction 
Significant decreases in systolic blood pressure are not uncommon during dobutamine stress 
echocardiography.  The  definition  of  hypotension  is  generally  accepted  as  a  fall  of  more  than  20 
mmHg.14 Unlike the prognostic  significance of hypotension during exercise stress testing,  a fall  in 
blood pressure with dobutamine is not associated with adverse prognosis and is not a marker of severe 
CAD.15
Several mechanisms have been proposed as the cause for the hypotension in the absence of 
worsening left ventricular function. A secondary vasodepressor response, development of a dynamic 
intraventricular  gradient13,  79,  failure  to  increase  the  cardiac  output,  decrease  in  systemic  vascular 
resistance and left ventricular cavity obliteration may work alone or in concert to cause hypotension.
Dobutamine Stress Echocardiography Protocols
There is no universal standardized infusion protocol, including initial dose (2.5 µg/kg/min to 10 
µg/kg/min),  stage  duration  (2  to  10  minutes)  and  maximum dose  (30  to  50  µg/kg/min). 16 Many 
protocols used an age predicted maximum heart rate and 85% of the target heart rate. The infusion 
protocol is often a function of the clinical setting, perceived pretest probability of disease, resting left 
ventricular function and the clinical question.
Initial experience with DSE emphasized safety concerns and thus early protocols began with 
relatively low doses. As the experience with dobutamine increased the initial infusion rates of 5 to 10 
µg/kg/min and increased by 10 µg/kg/min every 2 to 3 minutes to a maximum of 40 to 50 µg/kg/min 
are being used.7 
Prolonged duration of stages may potentially improve the sensitivity of the test, decrease the 
need for  atropine and require  a lower peak dose to  achieve target  heart  rate.  It  also allows better  
evaluation of myocardial viability with fewer side effects. At present most laboratories use 3 minute 
stages. For patients who do not achieve 85% of the target heart rate after the maximum dobutamine 
dose, 0.2 to 0.5 mg of atropine every 1 to 3 minutes to a maximum of 1 to 2 mg is given along with the  
dobutamine infusion. Patients on β blockers are more likely to require the addition of atropine. Unless 
the goal of the test is to assess medical therapy, β blockers should be discontinued 24 to 48 hours prior  
to the testing. 
It is also reported that a heart rate of less than 70 beats per minute at the 20 µg/kg/min dose 
stage or an increase in heart rate from the base line at 20 µg/kg/min of less than 5 beats per minute are  
accurate  predictors  of  the  need  for  atropine.  If  the  above  mentioned  finding  is  noticed  at  the  20 
µg/kg/min stage atropine can be used before achieving the 40 µg/kg/min stage.17 This significantly 
shortens the time of study but the impact on the sensitivity and specificity are not clearly known. 
Isometric hand grip can also be used to achieve the target heart rate in the later stages.18
Infusion Endpoints
The dobutamine infusion is continued until one or more predefined end points are reached. In 
the absence of other endpoints or intolerable side effects, the infusion is continued until the patient’s 
heart rate reaches 85% of the age predicted maximum heart rate. 
The other end points are 
1. Significant new or worsening regional wall motion abnormalities
2. Severe symptoms, either cardiac or noncardiac
3. Severe increase in blood pressure (SBP > 240 mmHg or DBP > 120 mmHg) or symptomatic 
hypotension
4. Significant ECG changes, especially if accompanied by echocardiographic findings
5. Significant ventricular or supraventricular tachyarrhythmias
6. Completion of protocol usually at 40 – 50 µg/kg/min
Laboratory Setup and Personnel
The testing area should satisfy the following requirements19
1. Adequate space, with a minimum of 300 sq ft. is recommended. 
2. Appropriate resuscitatory equipment – Crash cart, Oxygen and suction equipment
3. Readily available medication to reverse the effects of dobutamine or to treat arrhythmias – 
Intravenous β blocker and IV calcium channel blockers
4. Infusion pump to regulate the delivery of dobutamine
5. Automate or manual blood pressure measuring apparatus
6. A 12 lead ECG machine
7. A echocardiography equipment that can record and replay digital images
Sample Protocol for Dobutamine Stress Echocardiography
1. Baseline echocardiographic views, 12 lead ECG and blood pressure. Continuous ECG 
recording with printout every minute.
2. Initial starting dose of 2.5 µg/kg/min for viability studies, 5 µg/kg/min for standard study or 
10 µg/kg/min for low risk group.
3. Echocardiography images obtained and evaluated approximately 1 minute after the start of 
dobutamine and before each increase.
4. Heart rate, blood pressure and 12 lead ECG at each stage. Each stage lasts 3 minutes.
5. After 20 µg/kg/min the dose is increased by 10 µg/kg/min intervals up to a maximum 
dosage of 40 – 50 µg/kg/min.
6. If infusion end point is not reached, atropine is given at 0.25 to 0.5 mg intravenously, 
continuing the current dobutamine dose. Additional doses of atropine can be given till 2 mg 
is reached.
7. The dobutamine infusion is discontinued if one or more of the end points mentioned above 
are reached.
Echocardiographic, Electrocardiographic and Vital Sign Monitoring
Baseline  heart  rate,  blood  pressure  and  12  lead  ECG  are  recorded  and  baseline 
echocardiographic  images  are  obtained.  A secure  peripheral  line  is  established  for  the  delivery of 
dobutamine.  Following  the  review  of  baseline  data  after  a  brief  history  from  the  patient  and 
determining  the  indication  for  the  study,  the  dobutamine  infusion  is  begun.  ECG  is  monitored 
continuously during the study. A 12 lead ECG is taken every minute and at the end of each stage, or if 
symptoms develop. Blood pressure is measured after 1.5 to 2 minutes into each stage or if symptoms of 
hypertension or hypotension develop. 
Patients are  monitored for a  minimum of  5 minutes  post  infusion or  until  vital  signs have 
returned to baseline (heart  rate below 100 beats per minute or 20 bpm of baseline, blood pressure 
returning to baseline or dysrhythmias resolved) and symptoms have resolved. Patient is monitored till 
all the ECG and echocardiographic changes have returned to baseline.
Safety and Complications of Dobutamine Stress Echocardiography
Dobutamine stress echocardiography has an excellent safety profile. Several large studies have 
specifically examined the safety issues in a variety of populations.2 They have reported low rates of 
significant  complications.  The  few  serious  complications  that  have  been  reported  are 
haemodynamically  significant  dysrhythmias.  There  are  rare  reports  of  acute  myocardial  infarction 
during DSE. This may be due to α1 mediated vasospasm, and the occurrence appears to be uncommon.
The largest series reported by Seckuns and Marwick21 evaluated a large number of patients and 
were followed up for 5 years. In spite of the aggressive protocols, there was no increase in the major  
side effects. Arrhythmias and hypotension were the most commonly reported complications. Serious 
complications like myocardial  infarction and sustained ventricular tachycardia occurred in 0.3% of 
patients. No deaths and incidences of ventricular fibrillation occurred.
The safety of DSE in post myocardial infarction patients was evaluated by Mertes20 and he 
reported no deaths, myocardial infarctions or sustained ventricular tachycardias. The commonest cause 
for stopping the test was for reaching the target heart rate (52%). Angina during the test was managed 
with sublingual nitrates or intravenous β blockers. Ventricular and atrial premature beats were observed 
in 15% and 8% respectively. Atrial flutter and fibrillation was noted in 1% of patients, which reverted 
spontaneously after stopping the infusion. 
In  a  multicentric  study  of  a  large  number  of  patients,  Picano22 reported  a  relatively  high 
incidence (0.5%) of significant and potentially life-threatening events with DSE. Patients suffered from 
myocardial  infarction,  ventricular  tachycardia,  ventricular  fibrillation,  hypotension  and  prolonged 
angina. They accounted for 12% of terminations of the test. Various others have evaluated the safety of 
DSE in other high risk groups like aortic aneurysm, early post MI and patients with organized apical  
thrombus23. One patient has suffered myocardial rupture at the 10 µg/kg/min stage and survived.24
Contraindications to Dobutamine Stress Echocardiography
The contraindications to DSE are similar to those of exercise stress testing. 
1. Acute coronary syndromes including unstable angina and acute myocardial infarction.
2. Uncontrolled heart failure
3. Uncontrolled ventricular or supraventricular tachycardia
4. Marked hypertension with a systolic blood pressure of more than 200 mmHg or a diastolic 
blood pressure of more than 110 mmHg.
5. Hypertrophic obstructive cardiomyopathy
6. Severe aortic stenosis
7. The use of atropine is contraindicated in patients with glaucoma and prostatic obstruction.
Clinical Uses of Dobutamine Stress Echocardiography
Dobutamine stress echocardiography is used in a variety of clinical settings including patients 
with chest pain syndromes for evaluation of coronary artery disease. It is also used in patients with 
established coronary artery disease to detect the functional status, to detect viability of myocardium in 
infarcted areas, in identification of the culprit vessel when the angiographic lesion shows borderline 
stenosis, to evaluate the response to medical, percutaneous or surgical therapy and risk stratification 
following  myocardial  infarction.  Additionally,  DSE  can  also  be  used  in  patients  after  cardiac 
transplantation, risk stratification in patients before noncardiac surgery and in evaluation of patients 
with valvular heart disease.
Evaluation of Patients with Chest Pain
Many tests are available to the clinician to evaluate patients with chest pain that is suspected of 
being caused by myocardial ischaemia. These include the standard exercise ECG, the stress perfusion 
imaging and pharmacological stress imaging. Of these modalities, DSE has emerged as an important 
tool in the assessment of chest pain. It becomes more important in patients who cannot exercise due to 
orthopaedic complications.
The initial study by Sawada for evaluating a patient for CAD with angiographic correlation 
showed a sensitivity of 89% and a specificity of 85% using the 30 µg/kg/min maximum dose protocol.  
All false negatives occurred in patients with single vessel disease and in those with a diameter stenosis 
of 40 – 50 %. In patients with resting regional wall motion abnormality, the sensitivity and specificity 
to detect ischaemia at a distance was 81% and 87% respectively. In another group Segar et al, reported 
a  sensitivity  of  95%  and  a  specificity  of  82%  in  a  group  of  patients  who  underwent  DSE  and 
quantitative angiography. Many other groups have reported similar figures in patients with single and 
multivessel disease.7
In a review of 28 studies published from 1991 to 1996, Geleijnse et al13 reported that based on a 
total of 2246 patients undergoing DSE, the sensitivity, specificity and accuracy of the test to detect  
CAD were 80%, 84% and 92% respectively.  The mean sensitivity for detecting single, double and 
triple vessel disease were 74%, 86% and 92% respectively. The sensitivity of DSE for the detection of 
CAD is purely a function of severity of the underlying disease, the protocol used and the achievement 
of adequate heart rate. Diagnostic sensitivity is compromised when adequate heart rate is not achieved. 
Addition  of  atropine  to  increase  the  heart  rate  has  been  shown to  improve  the  diagnostic 
accuracy. False positive studies may occur due to true ischaemia in the absence of angiographically 
significant stenosis, over interpretation of regional wall motion abnormality and regional differences in 
the  myocardial  thickening.  The  tendency  to  get  false  positive  test  is  more  in  the  basal  posterior 
circulation.
The  diagnostic  accuracy of  noninvasive  testing  in  patients  with  LBBB and left  ventricular 
hypertrophy is often challenging. Perfusion images often result in false positive studies in patients with 
LBBB. Small studies indicate that DSE may be more accurate in evaluating these patients with LBBB 
or LVH.13 This observation needs to be confirmed by larger trials.
Clinical Accuracy Compared to Other noninvasive Testing
In general, DSE compares well in terms of sensitivity, specificity and overall accuracy, with 
stress nuclear perfusion imaging, pharmacological stress imaging using vasodilators and exercise stress 
echocardiography and is superior to the exercise ECG and dobutamine stress ECG. When compared 
with treadmill ECG in patients who were evaluated for CAD, DSE proved better than treadmill ECG 
testing and dobutamine ECG testing. The direct comparison of dobutamine stress echocardiography, 
treadmill  stress echocardiography and dipyridamole stress echocardiography showed that they were 
comparable with angiography as the gold standard. Another study by Martin et al showed that DSE was 
more sensitive and better tolerated than either adenosine or dipyridamole. 
Marwick25 compared dobutamine  and adenosine  in  combination  with echocardiography and 
99mTc-MIBI  single  photon  emission  computed  tomography  imaging  and  noted  virtually  identical 
sensitivity between DSE and adenosine perfusion imaging. Thus dobutamine stress testing appears to 
be a reliable and accurate method of noninvasively assessing patients with chest pain.
Evaluation of Patients with Known Coronary Artery Disease
For patients with known coronary artery disease, there is often a need for a functional test to aid 
in the clinical decision making. Dobutamine stress echocardiography has become an important and 
reliable method to evaluate such patients who are unable to exercise. 
Owing to the ability of echocardiography to detect regional changes in left ventricular systolic 
function, DSE can help to localize myocardial ischaemia to a specific vascular territory. There is often 
a  need  to  evaluate  patients  in  a  variety  of  clinical  circumstances.  These  include  post  MI  risk 
stratification,  viability in the infarcted zone,  to detect ischaemia at  a distance,  to  detect  functional 
significance of angiographically borderline lesions, to detect the culprit vessel in multivessel disease 
before revascularization, to provide long term prognostic information, to assess response to medical 
and surgical revascularization and to evaluate patients with left ventricular dysfunction for the presence 
of viable and residual ischaemic myocardium.
Post Myocardial Infarction
The goals of post MI assessment including the evaluation of  residual ischaemia, or viability 
with or without ischaemia, in the infarct zone and evaluation of inducible ischaemia remote from the 
infarct13, which is an evidence of multivessel disease. Stress echocardiography including DSE, has been 
shown to be a safe and reliable tool in evaluation of this patient group.5, 13
Myocardial Viability
The differentiation of  dysfunctional  but  viable  myocardium, which  can be a  hibernating or 
stunned myocardium, from irreversible damaged myocardial  scar is important in the assessment of 
patients with depressed left ventricular function, in whom revascularization is contemplated. Overall 
left ventricular systolic function is an important determinant in the outcome of patients with chronic 
CAD. Thus identifying viable myocardium prior to attempts at revascularization is important because 
the  contractility  of  the  myocardium  that  is  successfully  revascularized  may  improve,  leading  to 
improved global left ventricular function and long term outcome. Dobutamine stress echocardiography 
is a reliable method of assessing viability of the myocardium.26
Post PCI and Other Patient Populations
Dobutamine  stress  echocardiography  has  been  used  in  patients  following  percutaneous 
revascularization procedures and after transmyocardial laser revascularization to determine the success 
of such revascularization procedures and to evaluate patients for the presence of residual ischaemia.27 
There is also a growing population of post cardiac transplantation patients who undergo DSE as a  
screening test to detect coronary allograft vasculopathy.28
RISK STRATIFICATION
The utility of DSE as a tool to stratify individuals according to risk factors has been evaluated in 
a variety of clinical settings.
The Value of a Negative Test
Dobutamine  stress  echocardiography  not  only  plays  a  role  in  the  diagnostic  evaluation  of 
patients  presenting with chest  pain but  also in  risk stratification of  these  patients.  Patients  with a  
negative DSE in general have an excellent long term prognosis.16
A group of 200 patients were studied by Geleijnse16 who presented with chest pain, a normal 
resting ECG and a negative DSE. They included patients with known CAD but excluded those who had 
undergone  revascularization  procedures.  The  patients  were  classified  into  low  risk  (<10%), 
intermediate risk (10–80%) and high risk (>80%) pretest probability of CAD depending on the clinical 
variables. On follow up, the patients who had events were the ones with high pretest probability and the 
ones who has a positive DSE.
Patients with Known Coronary Artery Disease
Steinberg et al followed a significant number of patients who underwent both DSE and coronary 
angiography for a period of 3-6 years. They found that cardiac mortality was significantly more in the 
positive  DSE group  compared  with  the  negative  DSE group  (9% versus  0%).  Dobutamine  stress 
echocardiography had an overall sensitivity and specificity for all cardiac events of 78.8% and 51.9% 
respectively and 100% and 37.2% for cardiac death respectively.  The negative predictive value for 
cardiac death was 100% and was 95.2% for myocardial infarction.
Preoperative Risk Stratification for Non-cardiac Surgery
Beginning in the early 1990s, pharmacological stress imaging has been used extensively in the 
assessment  of  patients  prior to  non cardiac surgery,  especially in  patients  with peripheral  vascular 
diseases.
The first large multicenric experience with DSE in the post infarct period was reported by Echo 
Dobutamine International Cooperative (EDIC) Study Group. Sicari et al published data on 778 patients 
on  whom DSE was  done 12 days  after  myocardial  infarction.  They found that  echocardiographic 
images were adequate for analysis in 97% of patients and the complication rate was extremely low 
(0.5%). Mortality was not significantly different between the groups with or without ischaemia (2.2% 
vs 1.1%) and the only predictors were the presence of ischaemia and left ventricular function.
Dobutamine Stress Echocardiography Compared with Nuclear Perfusion 
Imaging
The  overall  accuracy  of  pharmacological  stress  echocardiography  and  nuclear  perfusion 
imaging is similar. Therefore diagnostic test performance is usually not an issue in deciding between an 
echocardiographic versus a nuclear study. The experience and expertise of the local laboratories should 
play a role in deciding which test is to be performed. 
One potential clinical advantage of DSE compared with pharmacologic perfusion imaging with 
vasodilators is the ability of DSE to detect an ischaemic threshold. Owing to the ability to continuously 
monitor left ventricular function as the heart rate and blood pressure change during the infusion, one is 
able to determine the heart rate, and the rate pressure product, at which ischaemia becomes evident.  
This may correlate with the severity of the underlying CAD and may also have implications for risk 
stratification prior to noncardiac surgery. 
Dobutamine stress echocardiography does have many other advantages over nuclear techniques. 
It is clearly less costly not only in terms of initial startup cost but also in ongoing costs to maintain the 
laboratory and in the cost of the test to the patient. Because most hospitals and many outpatient offices 
already have cardiac ultrasound systems in place the need to acquire additional specialized imaging 
equipment other than the ability to have digital storage and display of the echocardiograms is avoided. 
Because no radiation is involved, it is potentially safer for both patients and the staff and the additional  
cost  in  terms  of  materials  and personnel  such as  nuclear  medicine  technicians  and complexity of 
working with radioactive materials  are  avoided.  Patients  with significant  bronchospasm can safely 
undergo a DSE whereas dipyrimadole is relatively contraindicated in these patients. Echocardiography 
also allows for a more thorough evaluation of the patient's cardiac status including an assessment of left 
ventricular systolic and diastolic function, valvular anatomy, the proximal aorta and the pericardium in 
addition to the evaluation for evidence of myocardial ischaemia. 
Echocardiography also has the advantage of immediate online result. It is more convenient for 
the patient and allows for the referring physician to be contacted with results immediately following the 
test. There is no need for the patient to return for delayed images or for the images to be processed for 
subsequent interpretation.
Application of Stress Echocardiography to Post infarct Risk Stratification
The  validation  of  stress  echocardiographic  techniques  in  the  diagnostic  and  prognostic 
assessment  of  chronic  CAD  has  been  discussed  extensively.  As  this  technique  may  define  left 
ventricular  dysfunction  and  exercise  capacity  and  detect  ischaemia  they may be  very  effective  in 
defining irreversible risk after myocardial infarction. The evaluation of these different approaches has 
been based on the ability to predict multivessel disease as a surrogate marker of reversible risk or direct 
evaluation of outcomes after various test results.
A number of different stresses have been employed in the post infarction patient. The following 
modalities are most often employed as a means of stress for echocardiographic imaging
1. Exercise Echocardiography
2. Dipyridamole stress echocardiography
3. Dobutamine stress echocardiography
Dobutamine stress echocardiography
The  methodology of  dobutamine  stress  echocardiography is  detailed  earlier.  Low doses  of 
dobutamine engender  augmentation of  function in  viable  myocardium.  High doses  of  dobutamine, 
especially  with  co-administration  of  atropine,  to  achieve  maximum  heart  rate  response  increased 
myocardial oxygen demand and thereby induced new or worsening regional wall motion abnormalities 
in regions supplied by stenotic coronary arteries. Thus, patients may be further stratified according to 
the presence of ischaemia, viability, or both.
The  contribution  of  ECG  responses  to  the  data  supplied  by  DSE is  probably  limited.  ST 
segment depression is not an important contributor to the diagnosis of ischaemia. The meaning of ST 
segment elevation is ambiguous. In the normal left ventricle, it is almost pathognomonic for ischaemia. 
Some authors have suggested that the more common finding of ST segment elevation occurring in 
leads with Q waves is indicative of myocardial viability. The preponderance of data however, suggests 
that this finding is not a predictor of viability. It may perhaps be a passive phenomenon related to  
dyskinesis  induced  in  akinetic  segments.29 In  subjects  treated  with  thrombolysis,29 ST  segment 
elevation during DSE may predict infarct related artery occlusion but it does not predict viability or 
ischaemic responses during DSE. 
Although  the  use  of  DSE for  the  detection  of  multivessel  disease  after  MI  was  originally 
reported a decade ago, the initial prognostic study of DSE following MI was reported only in 1996. Of 
41 subjects, 36 had a positive DSE with five negative tests. After an average 9.5 months of follow up,  
cardiac events including revascularization, occurred in 42% of DSE positive subjects versus 20% of 
DSE negative subjects.  Carlos et al examined 214 subjects after a mean of 4.5 days post infarction, 
among  whom 80  subjects  had  cardiac  events  during  follow up,  with  similar  frequency in  the  83 
revascularized  and  131  medically  treated  subjects.  The  sensitivity  and  specificity  for  multivessel 
disease were 66% and 98% respectively, and in the 6 patients with events who had multivessel disease 
on angiography missed by DSE, there were no hard events. Multivariate predictors of events were 
infarct  size  (>3segments)  on  low dose  DSE nonviability  of  the  infarcted  region  and  presence  of 
multivessel disease on peak dose DSE, which was a better predictor in medically treated subjects. Left 
anterior  descending  artery  and  multivessel  disease  predicted  events  in  both  revascularized  and 
medically treated groups.
Assessment of Myocardial Viability
Over the past two decades,  there has been an increased realization that systolic myocardial 
dysfunction,  outside  of  the  setting  of  acute  ischaemia,  does  not  necessarily  imply  irreversible 
myocardial  injury.  Viable  myocardium  is  traditionally  defined  as  dysfunctional  myocardium  with 
reduced contractility which improves after restoration of adequate coronary blood flow. 
Myocardial viability has been described in two closely linked syndromes, myocardial stunning 
and myocardial hibernation. Stunned myocardium is a state of persistent contractile dysfunction with 
delayed recovery of function after transient ischaemia despite adequate reperfusion. A phenomenon 
originally described in animal models, myocardial stunning is clinically observed in the setting of acute 
coronary  syndromes.  On  the  other  hand,  hibernating  myocardium  refers  to  chronic  ventricular 
dysfunction associated with severe coronary artery disease, which exhibits complete or partial recovery 
of function after revascularization. Despite being considered separate entities, myocardial hibernation 
and stunning frequently co-exist  clinically,  particularly in  patients  with significant  coronary artery 
stenosis.
Several, modalities have been used for the identification of viable myocardium. These include 
dobutamine  stress  echocardiography,  magnetic  resonance  imaging,  membrane  integrity  with 
radionuclide techniques and metabolic activity with the use of positron emission tomography. More 
recently  myocardial  contrast  echocardiography  has  shown  promise  as  an  additional  method  for 
detecting viable myocardium by assessing microvascular integrity. 
Myocardial Stunning
Myocardial stunning was initially described in experimental animals after a period of coronary 
occlusion  followed  by reperfusion.  After  a  period  of  coronary occlusion  for  2  hours  followed by 
reperfusion, regional dysfunction improved over a period of 2 – 3 weeks. The postischaemic contractile 
dysfunction may be multifactorial, the result of oxygen free radicals, abnormalities in calcium flux, and 
local accumulation of neutrophils. In the clinical setting, myocardial stunning can be observed after 
reperfusion  therapy for  acute  myocardial  infarction  and  in  patients  with  unstable  angina  coronary 
syndromes or exercise induced ischaemia.
Prediction of Reversible Dysfunction with DSE after Myocardial Infarction
The demonstration of inotropic reserve forms the basis of detection of viable myocardium with 
DSE. In the early phase of applying these concepts in a clinical setting, Pierard et al, evaluated low 
dose dobutamine (10 µg/kg/min) in patients after acute myocardial infarction and compared results 
with  positron  emission  tomography.  A 79% concordance  in  the  evaluation  of  viability  was  found 
between  the  two techniques.  Since  then,  it  is  now well  established that  augmentation  of  regional 
function in response to low dose dobutamine, soon after myocardial infarction (less than 2 weeks), 
accurately predicts recovery of residual viable myocardium.
Smart et al studied patients within 7 days of myocardial infarction. Forty three percent showed 
improvement in resting regional wall motion abnormality with low dose DSE (4 µg/kg/min), with a 
sensitivity of 86%. Congruent  data  has been obtained by Watada et  al  in  patients with reperfused 
anterior  myocardial  infarction,  with a sensitivity and specificity of  83% and 86% respectively,  for 
detecting improvement in function. Previtali et al examined patients who were thrombolysed within 6 
hours of presentation.  DSE was performed at a mean of 8  + 4 days after infarction and showed a 
sensitivity of 79% and a specificity of 68% in predicting contractile recovery.
Clinical Relevance of Myocardial Viability after Myocardial Infarction
The presence of myocardial viability shortly after acute myocardial infarction has been well 
documented  and  may  be  a  predictor  of  subsequent  ischaemic  events  in  the  presence  of  residual 
coronary artery stenosis. Ventricular impairment, which may exist because of a compendium of scar 
and viable myocardium in the post infarction setting, may significantly affect the outcome of these 
patients. An analysis of patients from GISSI-2 study has shown that early left ventricular failure and 
recovery  phase  left  ventricular  dysfunction  are  two  of  the  most  powerful  predictors  of  6  month 
mortality following acute myocardial infarction.
Recently, Bolognese et al have demonstrated progressive LV dilatation in patients who showed 
no evidence of residual viability after reperfusion for acute myocardial infarction. Thus, revascularized 
viable tissue may favorably affect ventricular remodeling, which is a major determinant of mortality 
following  myocardial  infarction.  The  potential  role  of  viable  myocardium  at  risk  in  promoting 
ischaemia, electrophysiological instability, and ventricular remodeling post infarction have also been 
proposed as plausible mechanisms by which prognosis may be altered.
The prognostic impact of DSE in patients following an acute myocardial infarction has been 
evaluated recently. In the two trials that evaluated this group, Sicara et al30 performed DSE, up to 40 
µg/kg/min, in a large group of patients at 12 + 5 days after a first uncomplicated myocardial infarction. 
The  presence  of  viability  at  low  dose  DSE  was  the  strongest  predictor  of  spontaneous  events, 
predominantly unstable angina. Wall motion score index at peak stress and remote ischaemia, however,  
were much stronger predictors of hard events like cardiac events and nonfatal myocardial infarction. 
Carlos et al31 studied patients 2 to 7 days after acute myocardial infarction and found that infarction 
zone nonviability and ischaemia or infarction at  a distance was among the strongest predictors for 
adverse outcome. The uncontrolled medical and surgical management of these patients, coupled with 
differences  in timing of  DSE in relation to  the onset  of  infarction and recovery of function,  limit 
inferences regarding whether viability by itself is a good or bad prognostic variable in the post infarct 
period. The impact of residual viability may depend on the period of study after the infarction, the 
initial management of infarction and the presence of residual ischaemia in the infarct territory. The 
presence of provocable ischaemia remains an important indicator for prognostication.30 It also appears 
to be superior information than coronary anatomy at cardiac catheterization.31
Myocardial Hibernation
It is postulated that in some patients with coronary artery disease, the myocardium may respond 
to  chronic  hypoperfusion  by downregulating  contractile  function,  thereby reducing  cardiac  energy 
demands.32 Myocardial hibernation, a name originally coined by Rahimtoola, describes such a state in 
patients with chronic ischaemic heart disease, in whom restoration of coronary flow allows recovery of 
ventricular contractile function.33,34 
Although early studies suggested that resting blood flow in this syndrome is reduced, more 
recent data with quantitative flow measurements indicate that resting blood flow may be normal or is 
moderately  reduced,  with  disproportionate  decline  in  contractile  function.35,36 This  had  led  to  the 
proposal that contractile dysfunction in myocardial hibernation may involve, at least in part, an element 
of repetitive myocardial stunning, which manifests as protracted contractile dysfunction. Patients with 
myocardial  hibernation  have  an  increased  risk  for  future  cardiac  events,  hence  the  importance  of 
identification of such patients that may benefit from revascularization.37,38
The  cellular  and  molecular  mechanisms  underlying  hibernating  myocardium36 remain 
incompletely  understood.  This  is  largely  due  to  the  paucity  of  human  data  and  inadequacy  of 
experimental data in chronic hibernation. Myocardial hibernation is an adaptive mechanism that allows 
myocyte  survival  in  areas  of  marginal  perfusion.  Data  from  transmural  biopsies  from  patients 
undergoing coronary artery bypass surgery have shown a variety of histological changes, including 
depletion  of  contractile  apparatus,  glycogen  accumulation  and  loss  of  organized  endoplasmic 
reticulum.41 Borgers et al41 have suggested that the distribution of fibronectin, α-smooth muscle actin, 
cardiotin  and  titin  in  hibernating  myocytes  reflects  dedifferentiation  in  viable  myocardium  with 
regression of fetal phenotypes. This had been challenged by others, however, and recent studies have 
been inconsistent in this regard.45 
Newer  data  have  started  appearing  correlating  myocardial  histopathology  with  functional 
recovery in hibernating myocardium, showing that the extent of myocardial fibrosis is an important 
determinant of postoperative recovery of function.42, 43, 44 Recent data also suggests that the severity of 
histological  change  may also  depend  on the  duration  of  myocardial  hibernation,  with  progression 
toward irreversibility with time.45,  46 These findings coupled with data on the prognostic  impact of 
myocardial hibernation, further stress the importance of increased awareness and early detection of 
myocardial  viability in  patients with depressed ventricular  function and significant  coronary artery 
disease.
Detection of Myocardial Hibernation with Dobutamine Stress Echocardiography
 It is well established that hibernating myocardium exhibits contractile reserve in response to 
inotropic stimulation. This has been documented as early as the 1970s during cardiac catheterization.47, 
48 This has also been shown in experimental models of short term hibernation. Further clinical evidence 
has been more recently accumulated with the use of dobutamine stress echocardiography.49 Several 
studies in chronic left ventricular dysfunction have now corroborated the view that contractile reserve 
demonstrated by dobutamine stress echocardiography is highly predictive of functional improvement 
after revascularization.49 Cigarroa et al51 evaluated a few patients with multivessel coronary disease and 
left ventricular dysfunction and found an 82% predictive value for functional recovery. Since then other 
studies  have  been  published  using  low  dose  dobutamine  stress  echocardiography  of  10  to  20 
µg/kg/min.  Augmentation  of  regional  function  with  dobutamine  in  dysfunctional  segments  was 
predictive  of  recovery  of  function  after  revascularization.  Sensitivity  for  recovery of  function  has 
ranged from 74% abd 88%, with specificity between 73% and 87%.49 Sensitivity in akinetic segments 
appears to be lower than in hypokinetic segments.52 
Clinical  and  experimental  observations  demonstrate  that  contractile  reserve  is  present  but 
limited in myocardial hibernation.49 An increasing inotropic stimulation leads to depletion of energy 
stores, resulting in ischaemia. The use of high dose in addition to low dose dobutamine in patients with 
suspected  myocardial  hibernation  has  unmasked  differences  in  contractile  reserve49,  that  have 
significant  implications  for  the  prediction  of  recovery  after  revascularization.  Some  data49 have 
established the importance of using high dose dobutamine (40 µg/kg/min) in conjunction with low dose 
dobutamine to detect hibernating myocardium. 
Myocardium showing  regional  dysfunction  showed  one  of  the  four  characteristic  responses  to 
dobutamine.
1. Biphasic response, with augmentation at low dose followed by deterioration at higher doses.
2. Sustained response; improvement at low dose that persisted or further improved at higher doses.
3. No change.
4. Worsening of function, without contractile reserve.
5. New onset regional wall motion abnormality with dobutamine
A biphasic contractile response had the highest predictive value of 72% for recovery of function, 
followed by worsening only (35%).  Sustained improvement  and no change in  contractile  function 
showed  poor  predictive  values  (15% and  13% respectively).  The  deterioration  of  function  of  the 
segments  with  biphasic  response  was  usually  seen  at  20  µg/kg/min  of  dobutamine.   History  of 
exertional  angina  alone  was  a  poor  predictor  of  functional  recovery (36%).  Thus  the  presence  of 
viability with ischaemia appears  to  be the most  predictive of  functional  recovery.  An increased in 
sensitivity for recovery of function occurs when considering other responses in addition to biphasic 
response as a criteria for viability.49 
The low predicative value of sustained improvement response to dobutamine for functional 
recovery  emphasizes  the  difference  between  ‘myocardial  viability’ and  functional  recovery  after 
revascularization in patients with chronic ventricular dysfunction. Although augmentation of function 
with  dobutamine  is  inherently  an  indicator  of  viability,  the  continued  improvement  in  myocardial 
function  with  increasing  doses  of  dobutamine  supports  the  notion  that  these  segments  are  not 
ischaemic,  even during stress.  Chronic resting ischaemia or repetitive stress induced ischaemia are 
therefore not  the underlying mechanism for  resting dysfunction.  Revascularization in  this  situation 
would be expected not to improve the resting wall motion abnormality.  In patients with coronary artery 
disease, these segments probably represent areas of subendocardial infarction with residual stenosis 
that is not flow limiting or tethered myocardium. The sustained improvement response to dobutamine 
would also be expected in patients with nonischaemic cardiomyopathy.53 Arnese et al54 The sensitivity 
of DSE of in comparison to myocardial perfusion techniques may be lower (74% vs 89%), but the 
specificity is higher (95% vs 48%). Similar findings were observed by Perrone-Filardi et al.55 
Contractile function Versus Perfusion
The factors that determine the contractile response of viable myocardium to dobutamine are 
severity of coronary stenosis,  coronary reserve,  extent of collaterals,  cellular degeneration,  cellular 
metabolism and myocardial tethering. Radionuclide myocardial uptake and myocardial thickening at 
low dose have been shown to relate to the extent of fibrosis evaluated from biopsies at surgery.42 As 
mentioned previously, contractile reserve is generally less sensitive but more specific than perfusion 
imaging for predicting recovery of function after revascularization. 
It is now well established that the subendocardium contributes more significantly to myocardial 
thickening  than  the  subepicardium  especially  from  animal  models.  Implications  of  the  extent  of 
infarction  on  recovery  of  resting  function  and  on  detection  of  viability  by  techniques  relying  on 
contractile reserve, using dobutamine stress echocardiography or perfusion using nuclear techniques 
have  been  published.  Discordance  between  these  techniques  is  usually  seen  in  patients  with 
intermediate extent of subepicardial viability and not in the patients with high or low likelihood of 
viability. Depending on the extent of necrosis, dobutamine may or may not elicit thickening and resting 
function may or may not recover, whereas perfusion imaging is more likely to be positive. Data from 
explanted  hearts  and  from  myocardial  biopsies  at  surgeries  have  supported  this  postulate  and 
demonstrated that when discordance in the determination of viability exists between contractile reserve 
and perfusion parameters, the presence myocardial fibrosis is intermediate. Whether revascularization 
of myocardium with evidence of viability but without  subsequent recovery of resting function has 
beneficial implications for heart failure and ventricular remodeling, electrical instability and survival 
remain to be determined.  
Some studies56 have shown recovery of contractile function in areas that showed no recovery of rest 
function  showing  that  recovery  of  resting  function  may  underestimate  the  presence  of  viable 
myocardium  and  the  therapeutic  benefit  of  revascularization.  Reduced  left  ventricular  systolic 
dysfunction is one of the strongest predictors of poor outcome in patients with coronary artery disease. 
Hibernating myocardium may strongly contribute to ventricular impairment in these patients. Recovery 
of left ventricular dysfunction after revascularization of viable myocardium has been shown in many 
studies.  This  also  may  translate  directly  into  improved  prognosis. 

Conclusion
The presence of viable myocardium, detected by either dobutamine stress echocardiography or 
nuclear techniques, has consistently appeared as an important prognostic marker in patients with left 
ventricular  systolic  dysfunction.  Several  features  of  viable  myocardium  may  explain  the  benefits 
derived  from  its  revascularization:  ventricular  dysfunction,  which  contributes  directly  to  reduce 
exercise  tolerance  and  increased  mortality,  may  be  reversed;  progression  to  frank  ischaemia  and 
necrosis  may further  worsen  prognosis.  Long-term ventricular  dysfunction  secondary  to  structural 
remodeling may be affected by the extent and location of viable myocardium. Viable tissue may be a  
potential source of electrophysiological instability. Several factors in addition to viability, however, are 
involved  in  the  decision  making process  to  revascularize  patients  with  significant  coronary artery 
disease  and  left  ventricular  dysfunction.  These  include  the  presence  and  severity  of  angina  or 
ischaemia,  severity  and  extent  of  coronary  artery  disease,  adequacy  of  target  vessels  for 
revascularization,  ventricular  function  and  overall  risk  of  bypass  surgery  or  percutaneous 
revascularization. Patients who have significant angina, multivessel coronary artery disease and left 
ventricular dysfunction benefit from revascularization.80 Viability, its presence and extent are important 
determinants in the prognosis in patients with coronary artery disease and left ventricular dysfunction. 
The  remaining  issue  is  the  best  therapeutic  approach  to  patients  without  significant  demonstrable 
viability.78 With  the  current  advances  in  medical  treatment  for  heart  failure  and  interventional 
techniques for  coronary artery disease,  whether  the absence of  myocardial  viability is  best  treated 
medically or with coronary interventions remains to be determined in larger trials.
Materials and Methods
The study was conducted in the  Department of Cardiology at the  Stanley 
Government  Hospital,  Chennai.  Patients  who  were  admitted with  acute 
myocardial  infarction  to  our  department,  who  fulfilled  the eligibility 
criteria and did not have the exclusion criteria, were enrolled for the  study. 
Patients were studied either before discharge or called for the study on a predefined date. 
Patients were followed up at monthly intervals when they came for their biweekly drug review. 
They were examined clinically and all the vital parameters were recorded. A rest ECG was taken and a 
detailed history regarding their symptoms was obtained. Episodes of unstable angina and symptoms of 
heart failure were recorded and analyzed. If the patients had undergone any procedures the same was 
recorded and the patients were advised accordingly. Patients were followed up for six months. 
All  the  patients  who  participated  in  the  study  were  patients  admitted  to  our  hospital.  An 
informed consent was obtained and the purpose of the study was explained in detail. Patients were 
advised  to  undergo  coronary  angiography  according  to  their  dobutamine  stress  echocardiography 
results. Coronary angiography was not advised for all the patients because angiographic parameters 
were not included in the risk stratification protocol.
Methods
The patients for the study were selected from the population that was admitted to our hospital. 
The study was conducted from January 2005 to August 2005 and the patients who were admitted in the 
time period were studied. Though DSE is done regularly at our institution, the prognostic implications 
were not studied earlier. The inclusion criteria included
1. Patients who had myocardial infarction as evidenced by ST elevation, of more than 2 mm in 
chest leads and more than 1 mm in limb leads, in more than two concordant leads associated 
with chest pain.
2. Patients who were willing for the study and had the motivation for a regular 6 month follow up. 
3. Patients with adequate echocardiographic window during early assessment of left ventricular 
function.
The exclusion criteria included the following parameters
1. Patients  with  ongoing  myocardial  ischaemia,  congestive  cardiac  failure  and  recurrent 
arrhythmias
2. Patients who had poor acoustic window during initial examination
3. Patients with glaucoma or other contraindications for atropine
4. Patients who were above 75 years
5. Patients who were unwilling and did not want follow up.
After  the  initial  screening and exclusion,  46 patients  were selected for 
the study and were enrolled in  the Dobutamine Stress Echocardiography Register.  All  the patients 
underwent dobutamine stress echocardiography at our echocardiography lab after 11.89  + 4.44 days 
using  the  Aloka  ProSound  4000 machine,  which  is  installed  with  the  dobutamine  stress 
echocardiography package. Since heart failure, persistent angina and shock have been shown to be 
strongly associated with mortality and morbidity those parameters were excluded to avoid the masking 
of subtle parameters. 
The following protocol was followed to evaluate the patients. The protocol was adopted from the 
standard text books and articles.
1. Baseline echocardiographic views, 12 lead ECG and blood pressure were recorded.
2. A Continuous ECG recording with a printout every minute was obtained.
3. An initial starting dose of 2.5 µg/kg/min, for viability studies, 5 µg/kg/min for standard 
study or 10 µg/kg/min for low risk group was used.
4. Echocardiography images were obtained and were evaluated approximately 1 minute 
after the start of dobutamine and before each dose increase.
5. Heart rate, blood pressure and 12 lead ECGs were recorded at each stage. Each stage 
lasted for 3 minutes.
6. After 20 µg/kg/min the dose is increased by 10 µg/kg/min intervals up to a maximum 
dosage of 40 – 50 µg/kg/min.
7. If  infusion  end  point  was  not  reached,  atropine  was  given  at  0.25  to  0.5  mg 
intravenously,  continuing  the  current  dobutamine  dose.  Additional  doses  of  atropine 
were given till 2 mg is reached, if needed.
8. The dobutamine infusion was discontinued if one or more of the end points mentioned 
above were reached.
The following parameters were assessed during the study. 
1. Myocardial  function  –  Left  ventricular  systolic  function  using  Teichloz  method  and  using 
modified Simpsons method in patients with regional contractile dysfunction
2. Regional  wall  motion  assessment,  according to  the  American Society of  Echocardiography, 
with 16 segmental wall motion grading was done.
a. Normal = 1
b. Hypokinesia = 2
c. Akinesia = 3
d. Dyskinesia = 4
3. The wall motion score index (WMSI) was derived by dividing the sum of individual segment 
scores by the number of segments studied.
Test positivity was defined as the occurrence of one of the following features
1. New dyssynergy in a region with normal function
2. Worsening of resting dyssynergy
3. Biphasic response
4. Remote ischaemia
The presence of viability was defined as an improvement in regional function of grade 1 or more at 
low dose dobutamine (up to 10 µg/kg/min). Echocardiographic monitoring was performed throughout 
the study and for 5 minutes after the discontinuation of the infusion. The test was terminated for the  
routine indications for termination. 
Statistical Analysis
The collected data  was analyzed using the  Statistical  Package for  Social  Sciences software 
(SPSS Version-12). The individual effects of certain variables were analyzed with the use of the Cox 
model.  The variables selected for examination were age,  gender,  presence of diabetes,  presence of 
hypertension, smoking, refractory angina, Killips class,  thrombolysis, AWMI, effort tolerance after MI, 
left ventricular function after MI and WMSI at peak dobutamine dosage.
Various variables were compared by the unpaired two tailed t test. Proportions were compared 
by the Pearson chi-square value. Fisher exact test was used when appropriate. A p value of < 0.05 was 
considered statistically significant. Patients were grouped to comparable groups to obtain relevance if 
there were smaller number of patients. The final cardiac end points were also grouped into events and 
no events.
Results
Descriptive Statistics
 N Range Minimum Maximum Mean Std. Deviation
Age 46 51.00 24.00 75.00 52.4348 12.19044
Systolic BP 46 130.00 80.00 210.00 133.4783 29.90484
Diastolic BP 46 90.00 50.00 140.00 89.1304 18.71732
Admission Pulse 46 76.00 60.00 136.00 87.5000 19.70758
CP Duration 46 4,305.00 15.00 4,320.00 550.6522 882.93488
TIMI Score 46 7.00 1.00 8.00 3.7609 1.80351
Killips Class 46 3.00 1.00 4.00 1.2826 0.65534
Infarct Size 46 2.00 1.00 3.00 2.0652 0.61109
Effort Tolerance 46 2.00 1.00 3.00 2.1304 0.61855
Ejection Fraction 46 29.00 35.00 64.00 50.0652 6.44775
Days After MI 46 23.00 7.00 30.00 11.8913 4.44336
LV Fn. Basal 46 25.00 33.00 58.00 50.0652 6.03840
LV Fn.  Low 46 24.00 38.00 62.00 53.5435 6.42809
LV Fn.  High 46 38.00 33.00 71.00 58.1522 9.77063
Forty-six patients were studied and the mean age was 52.43 + 12.19. Among the 46 patients, 38 
(82.6%) were men and 8 (17.4%) were women (Figure 1). Most of the patients (16 patients – 34.8%)  
had an anteroseptal myocardial infarction, nine (19.6%) patients had extensive anterior wall myocardial 
infarction and six (15.2%) had inferoposterior myocardial infarction. The distribution of the areas of 
infarction is shown in Figure 2.
The pretest variables and the post test follow up variables were all compared to the various 
groups that were divided based on the result obtained from the dobutamine stress echocardiography 
test. The test conclusion was determined by predefined terms. 
• Group I – No regional wall motion abnormality at rest and no worsening of wall motion, 
with  normal  increase  in  contractility  to  dobutamine,  which  indicates  absence  of 
significant stenosis. 
• Group II - Regional wall motion abnormality is present at rest and it improves with low 
dose dobutamine and worsens with high dose (the classical biphasic response), which 
indicates viability with significant stenosis causing ischaemia.
• Group III - Regional wall motion abnormality is present at rest, which improves with 
dobutamine  and  continues  to  improve  with  increasing  doses  of  dobutamine,  which 
signifies stunned myocardium capable of improving with revascularization.
• Group IV - Regional wall motion abnormality is present at rest and does not improve or 
worsen with dobutamine, indicating absence of viability.
• Group V - Regional wall motion abnormality may or may not be present but the regional 
wall motion abnormality worsens with dobutamine, which signifies critical narrowing of 
the related coronary artery.
The results of the test are shown in the graph Figure 6. Group I had all the patients who showed 
a normal response to the test. This comprised of two (4.3%) patients who had no regional wall motion 
abnormality at rest and showed no worsening on stress. Group II had 18 (39.1%) patients who had 
viability without ischaemia with Group III having seven (15.2%) patients showing viability without 
ischaemia.  Group  IV had  14  (30.4%)  patients  who  showed  no  reaction  to  dobutamine  indicating 
myocardial scar. Group V had five (10.9%) patients who showed worsening ischaemia who probably 
had critical stenosis of the respective coronary artery.
Analysis of the Pretest Variables
The results  of the Dobutamine Stress Echocardiography (Normal,  viable without ischaemia, 
viable with ischaemia, not viable and ischaemia on stress) were compared with the pretest parameters. 
The various risk factors and their distribution are shown in Figure 4. Cross tabulations were made with 
all the individual variables and compared. Both men and women had similar findings during DSE, in 
other words, sex did not make a significant difference in the result after MI. Surprisingly the location of 
the infarct and the use of streptokinase also did not show significant differences in the conclusion of the 
test. The presence of a prior MI was a significant factor in influencing the presence of viability and a 
significant number of patients with a prior MI had absent viability as shown in Figure 13 (p=0.043). 
The presence of diabetes also significantly influenced the presence of ischaemia in viable tissue as 
depicted  in  Figure  11  (p=0.026).  The  normoglycaemics  had  more  viable  myocardium  without 
ischaemia than the ones with diabetes. Patients with hypertension also had a noticeable decrease in 
viability than normotensives but was not significant (p=0.09). 
Factors such as hypotension on admission, presence of an anterior wall myocardial infarction, 
ST elevation myocardial infarction and arrhythmias did not have a significant influence on viability 
during  the  post-infarction  dobutamine  stress  echocardiography.  Effort  tolerance  after  MI  was  a 
significant factor (p=0.029) in predicting viability after MI.
The  TIMI  score  and  the  Killips  score  for  myocardial  infarction  were  used;  there  was  no 
significant  difference  when  the  individual  results  of  the  study were  compared.  If  the  absence  of 
ischaemia was taken as a combined entity and if group 1 and 2 were combined, then the scores were 
significant in predicting the presence of ischaemia and viability.
One-way analysis of the variables and the results of DSE (Normal, viable without ischaemia, 
viable with ischaemia,  not viable and ischaemia on stress) showed that the older patients had less 
viability than the younger patients did and also more incidence of prior MI. The Killips score was 
highest (mean = 1.5 + 0.94) for the group that showed no viability. The pulse rate was also significantly 
different between the groups (p=0.016) and so was the basal myocardial function (p=0.001). 
When the ischaemia and nonischaemic groups were compared with presence and absence of 
events the difference between the groups was significant (p = 0.026). The use of Student’s T- test 
revealed a significant influence of TIMI score and ejection fraction. During the test the left ventricular 
ejection fraction during low dose and high dose were also significantly related to  the presence of 
ischaemia (p<0.001).  The presence of prior MI also showed significant influence in the presence of 
ischaemia in the viable zone.
The analysis of the pretest variables with the conclusion of the test revealed that the following 
variables predicted the presence of ischaemia in the presence of viability
1. The presence of prior myocardial infarction
2. The presence of Diabetes mellitus
3. The patient being a hypertensive
4. Patients with more than Killips I
5. Effort tolerance after MI of Class II or more
6. Tachycardia on admission
7. Basal left ventricular systolic function
Complications
Analysis of the test per se showed that it is a safe test and had very low complication rate. 
Among  the  patients  studied  37(80.4%)  patients  had  no  complications,  2  (4.3%)  patients  had 
hypotension, 1 (2.2%) patient had headache, 5 (10.9%) patients had ventricular ectopic activity and 
none had life threatening complications, as shown in Figure 5. 
Protocol Completion
It  was observed that  most  of  the patients (87%) attained their  target  heart  rate,  which was 
defined as 85% of the age predicted maximum heart rate (Predicted maximum heart rate = 220 – Age), 
with the routine protocol. Only two (4.3%) had inadequate response to dobutamine and out of that one 
patient was on a beta-blocker. These patients were included because their heart rate was 82% and 84% 
of the target heart rate respectively. 
In two patients who had a poor chronotropic response to dobutamine at 20 µg/kg/min, atropine 
was added earlier at 30 µg/kg/min and they were able to achieve their target heart rate.
Analysis of the Follow Up
The patients were followed up for 6 months at monthly intervals or whenever symptoms were 
present. The analysis was based on the conclusion of the test and the events related to the conclusion. 
Initial analysis of individual conclusions of the DSE (Normal, viable without ischaemia, viable 
with ischaemia,  not  viable  and ischaemia on stress) were analyzed with the individual  events  like 
unstable angina, myocardial infarction, heart failure or death. Since the number of patients studied were 
small and were distributed in the various DSE results, a statistical significance could not be observed.  
Once again, the conclusion was clubbed; as one with ischaemia or the one without ischaemia, since 
many earlier studies have shown that it is ischaemia that correlates with mortality and not the viability 
per se.  The events were also clubbed to show if the patients had an event or not instead of showing the 
individual events. 
There were a significant number of more events in the patients who had ischaemia with viability 
than in the patients who showed only viability – Figure 17. The events were seen more often in the 
third month  of  follow up (8.7%),  probably because of  the  return  to  manual  work and because of 
irregularity in taking their prescribed medications once they went for work. The patients who had poor 
viability and poor ejection fractions presented with more heart failures especially in the second month 
of follow up (6.5%). There was a steep increase in the procedure rate in the third month of follow up  
(10.9%). This was attributed to the waiting list at the Government General Hospital for the diagnostic 
procedure and the usual delay of two months to get the procedure done after a referral. 
In the final analysis, when the DSE result was compared with the events during follow up, 17 
(85%) patients who had no ischaemia had no ischaemic events – Figure 12 & Figure 14. Among the  
patients  who showed ischaemia,  12 (46.2%) patients  had  ischaemia  events  which  was  statistically 
significant (p = 0.026). The presence of ischaemia during stress after myocardial infarction, detected by 
dobutamine stress echocardiography, influenced the prediction of events more than the presence of 
viability alone. 
Discussion
The strong negative predictive value of dobutamine stress echocardiography was recognized in 
our study, which showed no events in the patients with a normal study. The patients who underwent the 
study were all post myocardial infarction patients, who were expected to have some amount of regional 
wall motion abnormality. Two patients had no regional wall motion abnormality at baseline and did not 
progress to show any deterioration of wall motion.
The presence of left ventricular dysfunction and regional wall motion abnormality are dominant 
factors in the prognosis of coronary artery disease. Similar patterns were seen in our study with a high 
level of significance (p < 0.001), when left ventricular function was compared between all the groups. 
The presence of viability has a major impact on the events after myocardial infarction, not just on 
mortality.  The analysis of pretest factors showed that certain factors contributed to viability and certain 
factors  predicted  ischaemia.  Presence  of  diabetes  predicted  the  presence  of  ischaemia,  than  in 
euglycaemics  who  showed  more  viability  without  ischaemia.  Surprisingly  patients  who  were 
thrombolysed showed significantly more number of patients with viability and ischaemia. The exact 
relevance of this observation is not clearly understood in this study and probably a study with more 
patients would clarify this issue. 
Similarly, smokers had more of non-viable myocardium than their non-smoking counterparts 
did.  It  is  also  interesting  to  note  that  none  of  the  smokers  had  a  normal  dobutamine  stress  
echocardiography and none of the non-smokers had an ischaemic response from normal baseline. This 
goes to show that smoking not only has an important role in the pathogenesis of myocardial infarction, 
it also has a significant role in the prognostic features by affecting the amount of viable myocardium,  
probably by influencing the response to treatment.
The  detection  of  the  presence  of  ischaemia  and  viability  using  dobutamine  stress 
echocardiography has been proven beyond doubt. The study focused on the variables that provided 
information on the prognostic details. Peak dobutamine wall  motion score index and an integrated 
assessment  of  the extent  and severity of ventricular  dysfunction at  peak stress  correlated with the 
severity of the underlying coronary artery disease and is the strongest predictor of subsequent cardiac 
events  and  death.  Stress  echocardiographic  testing  assesses  the  physiological  significance  of  the 
coronary stenosis but cannot predict events largely unrelated to plaque size, thrombus, ulceration of 
plaque, fissuring of plaque that leads to coronary occlusion.
Prognostic Meaning of Myocardial Viability 
After the pioneering study by Pierard et al, several groups have confirmed the observations that 
contractility with dobutamine predicts functional recovery of the dysfunctioning myocardium. In the 
light of these well-defined facts, it would be expected that myocardial viability would carry a potential 
positive prognostic impact. If the segment has inotropic reserve after dobutamine, it is likely to recover, 
and  left  ventricular  function,  a  major  prognostic  determinant,  is  likely  to  improve.  It  is  worth 
remembering that the presence of ischaemia affects the events and long term survival that the presence 
of viability alone. Active revascularization should be considered in all patients who show viability with 
ischaemia, since they have the best chance of improving left ventricular function with significant long 
term benefits. 
Conclusion
In  our  post  myocardial  infarction  dobutamine  stress  echocardiography  study,  which  also 
assessed the risk stratification and follow up for 6 months, the following conclusions were made
1. It is safe to do Dobutamine Stress Echocardiography in post myocardial infarction patients, 
even in the early post infarction period, with very low complication rate and risk to life.
2. Thrombolysis  had a significant effect on viability,  especially in the group, which showed a 
biphasic response.
3. Smoking affected the presence of myocardial viability significantly.
4. Patients with diabetes showed more biphasic response, signifying an increased prevalence of 
obstructive coronary artery disease.
5. Patients  with  normal  dobutamine  stress  echocardiography  had  no  events  on  follow  up, 
establishing its negative predictive value.
6. Patients who had a biphasic response had the maximum number of events compared to all the 
other groups. This group should be considered for early coronary revascularization.
7. The presence of a prior myocardial infarction predicted absence of viability and the absence of 
prior myocardial infarction predicted presence of viability.
8. Ejection fraction is a major predictor of events especially heart failure. It also predicted the 
coronary events significantly.
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DOBUTAMINE STRESS ECHO STUDY
Department of Cardiology, Government Stanley Hospital, Chennai.
Name                                              Age                Sex                CD Number                         
Address:                                                                                      Phone:                                  
Study Case Number                         Date                          Category I  /   II   /   III
Clinical Details
Basic Details
Infarct Terirory ASMI AWMI IWMI ExAWMI          HLMI
IWMI + PWMI IWMI + RVMI      Iso.PWMI
IWMI + RVMI + PWMI ASMI + IWMI   RVMI
Admission BP         mmHg    Pulse      bpm
SK Time Window         minutes Duration of chest pain      minutes
Previous MI Diabetes mellitus Hypertension Smoking
Tachycardia Hypotension Killips Class    I      II      III     IV
Anterior Wall MI STEMI Arrhythmias Ischaemia
Heart Failure Ongoing Ischaemia Embolic event Collapse
Size of Infarct Small            Moderate Large  Extensive
Effort Tolerance Poor Fair Good Excellent
Resting EF % Others                                                                              
Written Consent for DSE obtained ? Yes No
Number of days after Infarction 5 days 6 days More  days
                            Territory
Parameter
Baseline Low Dose High Dose Recovery
Response of Myocardium
RWMA region
Mitral Regurgitation
Global LV Function
KEY
Myocardial Response RWMA Region Mitral Regurgitation
1 – Normal 1 – Anterior wall 1 – Nil
2 – Hyperkinetic 2 – Lateral wall 2 – Mild
High Risk Variables
Dobutamine Stress ECHO
3 – Hypokinetic 3 – Inferior wall 3 – Moderate 
4 – Akinetic 4 – Posterior wall 4 – Moderately severe
5 – Dyskinetic 5 – Septum 5 – Severe
6 – Biphasic 6 – Apex 
DSE Conclusion:                                                                                                          
1  st   Follow Up: Date 
Any Events ?        Unstable Angina       Heart Failure      Arrhythmias          Infarction        Death
If Other Events – Details                                                                                               
Any Procedure ?    Coronary Angiography PTCA CABG
If Yes Details                                                                                                               
2  nd   Follow Up: Date 
Any Events ?        Unstable Angina       Heart Failure      Arrhythmias          Infarction   Death
If Other Events – Details                                                                                               
Any Procedure ?    Coronary Angiography PTCA CABG
If Yes Details                                                                                                               
3  rd    Follow Up: Date 
Any Events ?        Unstable Angina       Heart Failure      Arrhythmias          Infarction       Death
If Other Events – Details                                                                                               
Any Procedure ?    Coronary Angiography PTCA CABG
If Yes Details                                                                                                               
4  th    Follow Up: Date 
Any Events ?        Unstable Angina       Heart Failure      Arrhythmias          Infarction        Death
If Other Events – Details                                                                                               
Any Procedure ?    Coronary Angiography PTCA CABG
Follow Up
If Yes Details                                                                                                               
5  th    Follow Up: Date 
Any Events ?        Unstable Angina       Heart Failure      Arrhythmias         Infarction        Death
If Other Events – Details                                                                                               
Any Procedure ?    Coronary Angiography PTCA CABG
If Yes Details                                                                                                               
Study Conclusions and Details
                                                                                                                                    
                                                                                                                                    
                                                                                                               `                                 
Signature
Coding Sheet
Specific Codes General Coding 
Sex: 0 – No
1 – Male 1 – Yes
2 – Female
Infarct Area:
1 – Anteroseptal Myocardial Infarction
2 – Anterior Wall Myocardial Infarction
3 – Inferior Wall Myocardial Infarction
4 – Extensive Anterior Wall Myocardial Infarction
5 – High Lateral Myocardial Infarction
6 – Inferior Wall Myocardial Infarction  + Posterior Wall Myocardial Infarction
7 - Inferior Wall Myocardial Infarction + Right Ventricular Myocardial Infarction
8 – Isolated Posterior Wall Myocardial Infarction
9 - Inferior Wall Myocardial Infarction  
+ Posterior Wall Myocardial Infarction + Right Ventricular Myocardial Infarction
10 - Anteroseptal Myocardial Infarction + Inferior Wall Myocardial Infarction
11 - Right Ventricular Myocardial Infarction
12 – Inferolateral Myocardial Infarction
13 – Isolated Right Ventricular Myocardial Infarction
Regional Wall Motion Abnormality:
1 – Normal
2 – Hyperkinetic
3 – Hypokinetic
4 – Akinetic
5 – Dyskinetic
6 – Biphasic
Regional Wall Motion Abnormality – Location:
1 – Anterior Wall 
2 – Lateral Wall
3 - Inferior Wall
4 – Posterior Wall
5 – Septum
6- Apex
Mitral Regurgitation:
1 – None
2 – Mild
3 – Moderate
4 – Moderately Severe
5 – Severe
Protocol Completion:
1 – Completed
2 – Achieved Target Heart Rate at low dose
3 – Inadequate heart rate
4 – Stopped due to complications
Complications:
1 – None
2 – Hypotension
3 – Headache
4 – Atrial fibrillation
5 – Ventricular premature beats
6 – Supraventricular tachycardia
7 - Collapse
8 – Death
9 -  Myocardial Infarction  
10 – Persistent Angina
Conclusion:
1 – Normal
2 – Viability without ischaemia
3 – Viability with ischaemia
4 – No viability
5 – Worsening Ischaemia
Follow Up Events:
1 – None
2 – Unstable Angina
3 – Heart Failure
4 – Arrhythmias
5 – Infarction
6 – Death
Follow Up Procedures:
1 – None
2 – Coronary Angiography
3 – Percutaneous Coronary Intervention
4 – Coronary Artery Bypass Surgery
5 – Death during Procedure
Glossary
DSE – Dobutamine Stress Echocardiography
ECG – Electrocardiography
ECHO – Echocardiography
CAD – Coronary Artery Disease
LBBB – Left Bundle Branch Block
LVH – Left Ventricular Hypertrophy
MI - Myocardial Infarction
DBE – Dobutamine Echocardiography
WMSI – Wall Motion Score Index
AWMI – Anterior Wall  Myocardial Infarction
TIMI – Thrombolysis in Myocardial Infarction
Patient 1. Parasternal Long Axis Images
Patient 1. Parasternal Short Axis Images
Patient 2. Parasternal Short Axis Images
Patient 2. Parasternal long Axis Images
Figure 1. Sex Distribution
Figure 2. Infarction Territory
Figure 4. High Risk Variables
Figure 5. Complications
Figure 6. Viability Status 
Figure 7. Sex & Viability after MI
Figure 8. Thrombolysis & Viability after MI
Figure 9. Smoking & Viability after MI
Figure 10. Peak WMSI & Viability after MI
P < 0.001 P < 0.001
Figure 11. Diabetes & Viability after MI
P = 0.026
Figure 12. Events & Viability after MI
P = 0.047
Figure 13. Prior MI & Viability after MI
Figure 14. Presence of Ischaemia & Coronary Events 
Figure 15. Factors Predicting Ischaemia
p = 0.01
p = 0.023
p < 0.001.
p < 0.001.
